Skip to main content
OpenTrials

Clinical trial condition

Diffuse Large B-cell Lymphoma

Explore clinical trials studying Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

213 public trials 54 recruiting studies
Refine in advanced search Browse all conditions

Diffuse Large B-cell Lymphoma trial results

Active, Not Recruiting

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

NCT05658562

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Nagoya Medical Center Nagoya, Aichi-ken, Japan
  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Nagoya, Aichi-ken, Japan
  • National Cancer Center Hospital East Kashiwa-shi, Chiba, Japan
  • Kyushu Cancer Center Fukuoka, Japan
View all 23 locations
View Trial Details
Active, Not Recruiting

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840

Conditions
Acute Lymphoblastic Leukemia, Chronic Disease, Chronic Lymphocytic Leukemia, +23 more
Locations
  • University of California LA Los Angeles, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Uni of Chi Medi Ctr Hema and Onco Chicago, Illinois, United States
View all 37 locations
View Trial Details
Active, Not Recruiting

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Indiana Blood and Marrow Transplantation Indianapolis, Indiana, United States
  • Community Health Network Cancer Center North Indianapolis, Indiana, United States
  • University of Kentucky Markey Cancer Center Lexington, Kentucky, United States
  • Henry Ford Health System Jackson, Michigan, United States
View all 186 locations
View Trial Details
Active, Not Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

NCT04661007

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Aichi Cancer Center Hospital Aichi, Japan
  • Chiba Cancer Center Chiba, Japan
  • National Cancer Center Hospital East Chiba, Japan
  • University of Fukui Hospital Fukui, Japan
View all 23 locations
View Trial Details
Active, Not Recruiting

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

NCT07226752

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Affiliated Hospital of Hebei University Baoding, China
  • Beijing Cancer Hospital Beijing, China
  • Beijing Tongren Hospital, Capital Medical University Beijing, China
  • Peking University Third Hospital Beijing, China
View all 23 locations
View Trial Details
Active, Not Recruiting

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

NCT05429268

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Medical University Plovdiv Plovdiv, Bulgaria
  • Acibadem Cityclinica Mhat Tokuda Sofia, Bulgaria
  • Umhat Alexandrovska Sofia Sofia, Bulgaria
  • Umhat Sv. Ivan Rilski Ead Sofia, Bulgaria
View all 61 locations
View Trial Details
Active, Not Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028

Conditions
B Cell Malignancies, Chronic Disease, Chronic Lymphocytic Leukemia, +21 more
Locations
  • University of California Los Angeles Medical Center /ID# 246357 Los Angeles, California, United States
  • Yale University School of Medicine /ID# 259081 New Haven, Connecticut, United States
  • Mount Sinai Medical Center-Miami Beach /ID# 248251 Miami Beach, Florida, United States
  • Fort Wayne Medical Oncology and Hematology, Inc /ID# 250113 Fort Wayne, Indiana, United States
View all 39 locations
View Trial Details
Active, Not Recruiting

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • City of Hope National Medical Center /ID# 273338 Duarte, California, United States
  • Valkyrie Clinical Trials /ID# 269935 Los Angeles, California, United States
  • Desert Regional Medical Center /ID# 272437 Palm Springs, California, United States
  • Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823 Golden, Colorado, United States
View all 176 locations
View Trial Details

Related conditions